Clinical Trial Update: Monotherapy of an NMDA Enhancer for Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a monotherapy NMDA receptor enhancer for schizophrenia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• NMDA enhancer

Snippet

Sponsor: China Medical University Hospital | Conditions: Schizophrenia | Phase 2 | Status: RECRUITING